case_images: PMC11366576_01
case_images: Skin rash of the patient on admission.
case_images: fonc-14-1412021-g001.jpg
case_images: PMC11366576_01_fonc-14-1412021-g001.jpg
case_images: f1
case_images: Scattered erythematous rashes of hard texture and tender on palpation were noted across the trunk and limbs (refer to  Figure 1 ).
case_images: Whole-body PET-CT.
case_images: fonc-14-1412021-g002.jpg
case_images: PMC11366576_01_fonc-14-1412021-g002.jpg
case_images: f2
case_images: Bone marrow pathology: granuid erythroid hyperplasia, megakaryocyte hyperplasia (0-20/HPF), scattered or clustered, large and small megakaryocytes, online banking staining: grade 2.
case_images: fonc-14-1412021-g003.jpg
case_images: PMC11366576_01_fonc-14-1412021-g003.jpg
case_images: f3
case_images: During the second skin biopsy 11 days after admission, the skin red nodules increased significantly and the pain worsened.
case_images: fonc-14-1412021-g004.jpg
case_images: PMC11366576_01_fonc-14-1412021-g004.jpg
case_images: f4
case_images: Conducted on December 29th on a rash located on the back, the pathology of the second biopsy revealed no dysplasia in the epidermal squamous layer (refer to  Figure 4 ).
case_images: (A), CD2 (+), (B), CD3 (+), (C), CD4 (+), (D), CD5 (+), (E), CD7 (+), (F), CD8 (+), (G), CD20 (minority +), (H), CD56 (few +), (I), Ki67 (20-30% +), (J), GrB (+), (K), TIA-1 (+), (L), BCL2 (+). Result: (Right upper limb) Multifocal lymphocyte hyperplasia is seen subcutaneously, infiltrating between adipose tissue around the lamellar vessels, mixed with histiocytes. Combined with immunohistochemistry, it is considered as panniculitis.
case_images: fonc-14-1412021-g005.jpg
case_images: PMC11366576_01_fonc-14-1412021-g005.jpg
case_images: f5
case_images: Immunohistochemical analysis corroborated the diagnosis of panniculitis (refer to  Figure 5 ).
case_images: After treatment with rutinib and prednisone acetate, the rash gradually faded and the pain disappeared.
case_images: fonc-14-1412021-g006.jpg
case_images: PMC11366576_01_fonc-14-1412021-g006.jpg
case_images: f6
case_images: Therapeutic interventions initiated on January 2, 2024, including the administration of ruxolitinib at a dosage of 15 mg twice daily and prednisone at 65 mg per day, resulted in the normalization of the patient's body temperature, a gradual fading of the rash, and the alleviation of pain (refer to  Figure 6 ).